uniQure Q3 net loss widens to $89.6M ($1.88/sh); cash at $659M

uniQure N.V.

2023-Q3 EPS reported -$4.94 revenue$9,154,000

Net loss of $89.6M ($1.88 diluted EPS) vs $47.9M ($1.02 EPS) in Q3 2022; revenue flat at $1.4M.
Cash and investments $658.9M as of Sept 30, 2023; $180M cost savings expected to fund ops into Q2 2027.
FDA cleared IND for AMT-260 (epilepsy); AMT-130 (Huntington's) update expected later Q4 2023.
Strategic reorganization: 28% workforce cut, CSO Ricardo Dolmetsch departs, Richard Porter becomes Chief Business & Scientific Officer.
Received $100M milestone from CSL for first U.S. HEMGENIX sale; won 2023 Prix Galien USA Award.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

uniQure N.V. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001104659-23-115011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.